Evidence map›Paper›PMID 26074770›Full record

ArticleFrontiers in cellular neuroscience2015

Suppression of piriform cortex activity in rat by corticotropin-releasing factor 1 and serotonin 2A/C receptors.

Chakravarthi Narla, Henry A Dunn, Stephen S G Ferguson, Michael O Poulter

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Serotonergic afferents from the dorsal raphe decrease the excitability of pyramidal neurons in the anterior piriform cortex.Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  2. Article
  3. Article
  4. Article
  5. BK Channels Mediate Synaptic Plasticity Underlying Habituation in Rats.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2017
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Chakravarthi NarlaMolecular Medicine Research Group, Department of Physiology and Pharmacology, Robarts Research Institute, Faculty of Medicine, Schulich School of Medicine, University of Western Ontario London, ON, Canada.
Henry A DunnMolecular Medicine Research Group, Department of Physiology and Pharmacology, Robarts Research Institute, Faculty of Medicine, Schulich School of Medicine, University of Western Ontario London, ON, Canada.
Stephen S G FergusonMolecular Medicine Research Group, Department of Physiology and Pharmacology, Robarts Research Institute, Faculty of Medicine, Schulich School of Medicine, University of Western Ontario London, ON, Canada.
Michael O PoulterMolecular Medicine Research Group, Department of Physiology and Pharmacology, Robarts Research Institute, Faculty of Medicine, Schulich School of Medicine, University of Western Ontario London, ON, Canada.
Robarts Clinical Trials · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The piriform cortex (PC) is richly innervated by corticotropin-releasing factor (CRF) and serotonin (5-HT) containing axons arising from central amygdala and Raphe nucleus. CRFR1 and 5-HT2A/2CRs have been shown to interact in manner where CRFR activation subsequently potentiates the activity of 5-HT2A/2CRs. The purpose of this study was to determine how the activation of CRFR1 and/or 5-HT2Rs modulates PC activity at both the circuit and cellular level. Voltage sensitive dye imaging showed that CRF acting through CRFR1 dampened activation of the Layer II of PC and interneurons of endopiriform nucleus. Application of the selective 5-HT2A/CR agonist 2,5-dimethoxy-4-iodoamphetamine (DOI) following CRFR1 activation potentiated this effect. Blocking the interaction between CRFR1 and 5-HT2R with a Tat-CRFR1-CT peptide abolished this potentiation. Application of forskolin did not mimic CRFR1 activity but instead blocked it, while a protein kinase A antagonist had no effect. However, activation and antagonism of protein kinase C (PKC) either mimicked or blocked CRF modulation, respectively. DOI had no effect when applied alone indicating that the prior activation of CRFR1 receptors was critical for DOI to show significant effects similar to CRF. Patch clamp recordings showed that both CRF and DOI reduced the synaptic responsiveness of Layer II pyramidal neurons. CRF had highly variable effects on interneurons within Layer III, both increasing and decreasing their excitability, but DOI had no effect on the excitability of this group of neurons. These data show that CRF and 5-HT, acting through both CRFR1 and 5-HT2A/CRs, reduce the activation of the PC. This modulation may be an important blunting mechanism of stressor behaviors mediated through the olfactory cortex.

Indexed as

5-hydroxytryptamine receptorsadapting high frequencyadapting low frequencycorticotropin-releasing factorcorticotropin releasing factor 1 receptordimethoxy-4-iodoamphetaminenon-adapting very high frequencypiriform cortex

Identifiers

PMID26074770
PMCPMC4446537
OpenAlexW1484303089

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.